Talk:Galderma

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Switzerland Low‑importance

	Switzerland portal This article is within the scope of WikiProject Switzerland, a collaborative effort to improve the coverage of Switzerland on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.SwitzerlandWikipedia:WikiProject SwitzerlandTemplate:WikiProject SwitzerlandSwitzerland
Low	This article has been rated as Low-importance on the project's importance scale.

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

L'Oréal will pay €3.4 billion (USD$4.63 billion) for the remaining 27.3 million shares.[6]

This doesn't seem to make a whole lot of sense here, since Nestle bought Galderma. The source is not available anymore, unfortunately. Maybe the sentence is about a separate transaction? In this case, it should be deleted from the Galderma-page. - 130.60.152.125 (talk) 13:50, 3 March 2015 (UTC)[reply]

Proposal for updates

Hello,

We would like to add two pieces of content (either at the end of the History section, or into the Activities section), following the results of clinical studies, and are seeking the approval of the community.

First piece of content:

In June 2022, Galderma announced positive results in two Phase III trials for liquid botulinum toxin A, showing RelabotulinumtoxinA significantly reduced frown line severity and was well tolerated. This result primes the company to apply for approval in the US and other global markets.

Source: https://aestheticmed.co.uk/site/shownewsdetails/galderma-announces-positive-results-in-two-phase-i

Second piece of content:

In June 2022, Galderma announced positive data from Phase III trial, showing efficacy and safety of nemolizumab in patients with prurigo nodularis. Nemolizumab is a monoclonal antibody that blocks the signaling of IL-31, a neuroimmune cytokine involved in the pathogenesis of prurigo nodularis.

Source: https://clinicaltrials.gov/ct2/show/NCT04501666, https://finance.yahoo.com/news/galderma-announces-positive-data-phase-060000232.html

Many thanks for your feedback and advice,

Galderma21 Galderma21 (talk) 13:00, 20 December 2022 (UTC)[reply]

extensive COI editing

Article has been extensively edited by User:Galderma21, it needs a thorough review. In addition, User:Galderma21 appears to be a shared account by their own admission. — Preceding unsigned comment added by 46.140.57.254 (talk) 20:05, 25 April 2024 (UTC)[reply]